ReviewEMBO molecular medicine2022
Is there an unmet medical need for improved hearing restoration?
Review in EMBO molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Assessment of Safety, Tolerability, Pharmacokinetics, and Volume-Dependent Conductive Hearing Loss in Healthy Volunteers: First-in-Human, Open-Label, Placebo-Controlled Study of a Single Intratympanic Injection of AC102.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2025Trial
- Generation of marmoset monkeys with a non-mosaic disruption of the OTOF gene as a model of human deafness.Nature communications · 2026Article
- Efficient and sustained optogenetic control of sensory and cardiac systems.Nature biomedical engineering · 2026Article
- Channelrhodopsin variants for high-rate optogenetic neurostimulation at low light intensities.EMBO molecular medicine · 2026Article
- Observational
- Fucoidan-based Nanomedicine for Hearing Loss: Emerging Roles as Carrier and Therapeutic Agent.Pharmaceutical research · 2025Review
- IsMedComm · 2025Article
- Toward elucidating the mechanism of cochlear stimulation by infrared light.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Glycyrrhizic acid and its carrier-free micellar formulation: Unraveling the potential for enhanced oral prevention of hearing loss.International journal of pharmaceutics: X · 2025Article
- Advancing precision ear medicine: leveraging animal models for disease insights and therapeutic innovations.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Review
- Improved optogenetic modification of spiral ganglion neurons for future optical cochlear implants.Theranostics · 2025Article
- Catching up but still miles behind-a patient registry for otoferlin.Experimental & molecular medicine · 2024Article
- Gene therapy for deafness: are we there now?EMBO molecular medicine · 2024Article
- Clarin-2 gene supplementation durably preserves hearing in a model of progressive hearing loss.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- MSC-derived exosomes protect auditory hair cells from neomycin-induced damage via autophagy regulation.Biological research · 2024Article
- Using x-ray micro computed tomography to quantify intracochlear fibrosis after cochlear implantation in a Guinea pig model.Heliyon · 2023Article
- Recent advances and future challenges in gene therapy for hearing loss.Royal Society open science · 2023Review
- Patient perspectives on the need for improved hearing rehabilitation: A qualitative survey study of German cochlear implant users.Frontiers in neuroscience · 2023Article
- Is there an unmet medical need for improved hearing restoration?EMBO molecular medicine · 2022Review
- G protein-coupled receptors in cochlea: Potential therapeutic targets for hearing loss.Frontiers in molecular neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hearing impairment, the most prevalent sensory deficit, affects more than 466 million people worldwide (WHO). We presently lack causative treatment for the most common form, sensorineural hearing impairment; hearing aids and cochlear implants (CI) remain the only means of hearing restoration. We engaged with CI users to learn about their expectations and their willingness to collaborate with health care professionals on establishing novel therapies. We summarize upcoming CI innovations, gene therapies, and regenerative approaches and evaluate the chances for clinical translation of these novel strategies. We conclude that there remains an unmet medical need for improving hearing restoration and that we are likely to witness the clinical translation of gene therapy and major CI innovations within this decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.